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Abstract
Purpose To illustrate how structural equation modeling
(SEM) can be used for response shift detection with ran-
dom measurement occasions and health state operational-
ized as ﬁxed group membership (Study 1) or with ﬁxed
measurement occasions and health state operationalized as
time-varying covariates (Study 2).
Methods In Study 1, we explored seven items of the
Performance Scales measuring physical and mental aspects
of perceived disability of 771 stable, 629 progressive, and
1,552 relapsing MS patients. Time lags between the three
measurements varied and were accounted for by intro-
ducing time since diagnosis as an exogenous variable. In
Study 2, we considered the SF-12 scales measuring phys-
ical and mental components of HRQoL of 1,767 patients.
Health state was accounted for by exogenous variables
relapse (yes/no) and symptoms (worse/same/better).
Results In Study 1, progressive and relapsing patients
reported greater disability than stable patients but little
longitudinal change. Some response shift was found with
stable and relapsing patients. In Study 2, relapse and
symptoms were associated with HRQoL, but no change
and only little response shift was found.
Conclusions While small response shifts were found,
they had little impact on the evaluation of true change in
performance and HRQoL.
Keywords Response shift  Structural equation
modeling  Health-related quality of life  Multiple
sclerosis patients  Measurement bias
Introduction
Measurement in health research relies heavily on self-
report data. Self-report data collected in longitudinal
studies are often difﬁcult to interpret due to respondents’
changing standards, values, or conceptualization of the
target construct. This phenomenon is referred to as
‘response shift’. We distinguish three types of response
shift: (1) recalibration of respondents’ internal standards of
measurement, (2) reprioritization of respondents’ values,
and 3) reconceptualization of the target construct [1]. Each
of these types of response shift can be operationalized
within structural equation modeling (SEM) [2, 3].
Several operationalizations of response shift have been
proposed. Generally, response shift can be deﬁned either as
bias in the measurement of the attribute of interest or as
bias in the explanation of the attribute [4]. In this paper, we
will focus only on response shift in measurement. From
this perspective, bias is not considered as noise but rather
as systematic differences in patients’ scores that are not
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interest (e.g., health-related quality-of-life (HRQoL)), but
also by differences in other variables (e.g., other patient
expectations, adaptation). Response shift is considered as a
measurement bias that changes with time of measurement
in longitudinal research (see Oort et al. [2, 4, 5]).
With SEM, we can detect such measurement bias with
respecttotimeofmeasurementinlongitudinaldesigns,group
membership in multigroup designs, or any other exogenous
variable.Forexample,theeffectsofhealthstateonthecourse
of HRQoL can be modeled by dividing the sample into
healthy and non-healthy subgroups, or by including an indi-
cator of health state as an exogenous variable. If exogenous
variables are included in a longitudinal model, they can be
static (e.g., diagnosis) or they can vary across measurement
occasions (e.g., depression scale scores). Additionally, dif-
ferent longitudinal structures (e.g., growth, autoregression)
can be investigated with latent variables.
As explained in a companion paper by Schwartz et al. [6],
this paper is one in a series investigating response shift in
multiple sclerosis (MS) patients using different methods.
Here, we demonstrate how SEM can be used to detect
response shift. We aim to illustrate the ﬂexibility of SEM by
investigating response shift in two studies. In Study 1, we
investigate the performance disabilities in MS patients by
taking the ﬁrst three measurement occasions with varying
time lags across patients. We investigate health status by
distinguishingbetweenthreepre-deﬁnedandknowngroupsof
MS patients (i.e. stable, progressive, and relapsing) and use
these groups in a multigroup analysis. In Study 2, we inves-
tigate HRQoL in MS patients by selecting measurement
occasions with ﬁxed time lags. Health status is taken into
account by introducing time-varying health status indicators
as exogenous variables. In both studies, we will investigate
change and response shift with respect to health status.
Method
Data
Analyses in this paper utilize data from the North Ameri-
can Research Committee on Multiple Sclerosis (NAR-
COMS) project registry. The NARCOMS registry was
established in 1993 to collect biannual data on MS patients’
status. The main aim of the registry is to make these data
available for the wider community, in particular research-
ers, to increase knowledge about MS.
Study 1
Response shift in performance disability is investigated
using the intake questionnaire and the two subsequent
follow-up questionnaires. As the timing of the measure-
ment occasions varies across patients, they are considered
random. On average, the ﬁrst two measurement occasions
are 1.04 (SD = 0.79) years apart, and the second and third
measurement occasions are 0.88 (SD = 0.73) years apart.
Study 2
In Study 2, three other measurement occasions are used.
Since the intake survey does not include the HRQoL ques-
tionnaire,wetooktheﬁrstthreemeasurementoccasionsthat
included the HRQoL questionnaire and that were evenly
spaced in time (about 6 months apart). These occasions are
considered as ﬁxed. On average, the ﬁrst measurement
occasioninthisstudyis3.07(SD = 1.97) yearsfromintake.
Variables
In the NARCOMS registry, a number of demographic,
clinical, and psycho-social measures are collected. In Study
1, we investigate change and response shift in ‘perfor-
mance disability’ as measured by the Performance Scales
[7]. In Study 2, we investigate change and response shift in
‘HRQoL’ as measured by the SF-12 [8]. In both studies, we
include demographic variables (age and sex) and clinical
variables (time since diagnosis and health state). These
variables are used to investigate additional measurement
bias in the observed variables of the Performance Scales
and the SF-12.
Performance Disability
The Performance Scales [7] originally included eight items.
As the visual disability item was not consistently included
as part of the NARCOMS survey, we use seven items of
disability. Items were scored on a 6-point (or 7-point in
case of mobility) Likert scale (0 = Normal; 5 = Totally
disabled) and represent performance disability with respect
to mobility, hand function, fatigue, cognition, bladder/
bowel, sensory, and spasticity. Higher scores indicate
greater disability. When less than three item responses
were missing, values were imputed using the expected
maximization (EM) algorithm [9].
HRQoL
The SF-12 [8] was used to measure two components of
HRQoL: Mental (MENT) and Physical (PHYS). Eight
scales are created from the 12 items including physical
functioning (PF), role limitations because of physical
health (RP), bodily pain (BP), general health (GH), vitality
(VT), social functioning (SF), role limitations because of
emotional problems (RE), and mental health (MH). Higher
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123scores indicate better HRQoL. The scales—not the items—
are the focus of our analysis. When less then ﬁve subscale
values were missing, values were imputed using the EM
algorithm [9].
Health State
In Study 1, three groups of patients with different health
states were created based on their answers to relapse and
symptom change questions at baseline and follow-up mea-
surements. The three groups are deﬁned as follows: ‘stable’,
patients with no relapses and symptoms that remained
unchanged or improved; ‘progressive’, patients who
relapsed and whose symptoms continued to get worse;
‘relapsing’, those who experienced a relapse but whose
symptomsremainedunchangedorimproved.InStudy2,two
items were used to measure health state: ‘relapse in the past
6 months’ (1 = yes, 0 = no/unsure) and ‘symptoms com-
paredto6 monthsago’(1 = muchworse;7 = muchbetter).
Bothitemswereadministeredateachmeasurementoccasion
and can thus be included as time-varying covariates.
Other Variables
‘Age’, ‘sex’, ‘newly diagnosed’, and ‘time since diagnosis’
are also included in the analyses. At the ﬁrst measurement
occasion of Study 1, we distinguish between patients who
are newly diagnosed (diagnosis the same year as joining
the NARCOMS registry) and patients whose diagnosis year
was different from the year of joining NARCOMS or their
diagnosis year is unknown. In Study 2, ‘time since diag-
nosis’ is treated as a continuous variable that is calculated
as the difference between the ﬁrst measurement occasion
and the year of diagnosis. Patients with an unknown year of
diagnosis are excluded.
Study 1 analysis
In both studies, the analysis has three steps: Establishing a
measurement model (Step 1), testing invariance of model
parameters across measurement occasions (Step 2), and
testing invariance with respect to exogenous variables
(Step 3). Each step is outlined below, with similarities and
differences between the two studies highlighted. All anal-
yses were carried out with LISREL 8.54. See Appendix 1
for a more detailed description of the methods; syntax ﬁles
are available upon request.
Step 1: Establishing a measurement model
ThePerformanceScaleswereoriginallyreportedtomeasure
a unidimensional construct [7]. If the corresponding conﬁr-
matory factor analysis (CFA) model does not ﬁt, then
exploratory factor analysis is used to determine an alterna-
tive model, before continuing with CFA. Maximum likeli-
hood estimation is used for parameter estimation. We assess
the overall ﬁt of our models with the chi-square test of exact
ﬁt, the root mean square error of approximation (RMSEA)
[12], the expected cross-validation index (ECVI) [12], the
comparativeﬁtindex(CFI)[10],andtheTuckerLewisindex
(TLI)[11].Anon-signiﬁcantchi-squarevalueindicatesgood
ﬁt. However, as it is sensitive to small deviations between
modelanddata,especiallywhensamplesizeislarge,wealso
consider approximate ﬁt indices. RMSEA\0.08 indicates
satisfactory ﬁt; RMSEA\0.05 indicates close ﬁt. ECVI
cannot be used as a stand-alone index but can be used to
compare alternative models; a smaller ECVI value indicates
bettermodelﬁt[12].Finally,boththeCFIandtheTLIassess
the improvement in ﬁt from a null model that assumes no
relationships between variables. Values of[.90 forthe TLI
and values[.95 for the CFI indicate reasonable ﬁt of the
model to data. If a new model is speciﬁed, the change in
model ﬁt is assessed with the chi-square difference test and
the ECVI difference test [12].
Step 2: Testing invariance across measurement occasions
In this step, we take the ﬁnal model of Step 1 and simul-
taneously constrain all factor loadings and intercepts to be
equal across measurement occasions and groups. Across-
occasion invariance (no measurement bias) of factor
loadings and intercepts is assessed by comparing this
model with the ﬁnal model of Step 1 using the chi-square
difference test. A signiﬁcant result provides evidence for
response shift. However, if the test result is not signiﬁcant,
we still investigate response shift, as a single, yet sub-
stantially important response shift may not cause signiﬁ-
cant deterioration in the overall model ﬁt.
To detect measurement bias, we examine modiﬁcation
indices and the standardized expected parameter changes
(SEPC) [13]. If both are large, we expect signiﬁcant
improvement in the overall model and substantial change in
the parameter estimate(s). As there are a large number of
modiﬁcation indices to consider, we stop investigating
modiﬁcation indices when none are greater than a Bonfer-
roni-adjusted critical value [14] of 12.83. For SEPC, we
consider[0.10 signiﬁcant [15]. The effect size [16]o f
possibleresponseshiftswillbeevaluatedincomparisonwith
Cohen’s d effect sizes of observed and true change [2].
Step 3: Testing invariance with respect to exogenous
variables
The ﬁrst model in this step includes ‘age’, ‘sex’, ‘newly
diagnosed’, ‘time between measurement occasions 1 and 2’,
Qual Life Res (2011) 20:1527–1540 1529
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additional exogenous variables. These ﬁve exogenous
variables correlate with each other and with the common
factors, but their relationship with the observed items
should be fully explained through these correlations. If
large modiﬁcation indices and SEPCs are present, this
indicates the presence of bias. In case of direct effects
changing over time, we consider this measurement bias as
response shift.
Study 2 analysis
In Study 2, we took the same steps as in Study 1. All
analyses were carried out with Mx [17]. See Appendix 2
for a detailed description of the methods; syntax ﬁles are
available upon request.
Step 1: Establishing a measurement model
The ﬁrst goal is to ﬁnd a satisfactory measurement model
for the SF-12. We begin with the measurement model
comprising two common factors: PHYS and MENT
HRQoL. If this model does not ﬁt, we use modiﬁcation
indices and standardized residuals [13, 18] to identify
misspeciﬁcation and to develop an alternative model. As in
Study 1, possible model modiﬁcations are assessed using
the chi-square difference test and ECVI difference test.
Overall model ﬁt is assessed using the same statistics as
used in Study 1.
Step 2: Testing invariance across measurement occasions
All factor loadings and intercepts of the ﬁnal model of Step
1 are simultaneously constrained to be equal across mea-
surement occasions, like in Study 1. To detect response
shift, we use a different search strategy from Study 1 where
we test individual constraints. Here, we follow the proce-
dure outlined in King-Kallimanis et al. [19], relying on a
smaller number of global tests that free multiple constraints
simultaneously. In this study, we use eight global tests, one
for each observed scale. The ﬁt of each of these eight new
models is compared to the fully constrained model using
the chi-square difference test (at adjusted signiﬁcance
level) [14] and scaled observed parameter changes (OPC).
After running the eight tests, the observed scale producing
the largest OPC in combination with a signiﬁcant chi-
square difference test is interpreted as response shift. We
continue iteratively, retesting the remaining scales, until no
large OPC with a signiﬁcant chi-square difference test is
found. Corresponding to Cohen’s small effect sizes, we
consider an OPC indicating a standardized difference of 0.1
between factor loadings or 0.2 between intercepts to be
large [16].
Step 3: Testing invariance with respect to exogenous
variables
We extend the ﬁnal model of Step 2 to include ‘age’, ‘sex’,
‘time since diagnosis’, ‘relapse in the past 6 months’, and
‘symptom change in the last 6 months’ as exogenous
variables. To test for response shift, we ﬁt new models
where we include direct effects of the exogenous variables
on the observed scales. The impact of these direct effects is
assessed with OPCs and the chi-square difference test. If
the largest effects are signiﬁcant, we leave these parame-
ters free to be estimated and repeat the process until no
signiﬁcant improvements are found. Once any biases have
been accounted for, this ﬁnal model can be used to assess
true change in the attribute of interest using the same for-
mula used in Study 1 [2].
Results
Study 1 results
In the analysis of the Performance Scales items, we dis-
tinguished between 771 stable patients (26.1%), 629 pro-
gressive patients (21.3%), and 1,552 relapsing patients
(52.6%). See Table 1 for sample characteristics and
Table 2 for the Performance Scales item means.
Step 1: Establishing a measurement model
The reported unidimensional structure of the Performance
Scales yielded satisfactory ﬁt (Table 3, Model 1.1.1).
However, model ﬁt could be improved upon. Exploratory
factor analysis suggested a two-dimensional model, and in
CFA this model yielded substantially better ﬁt for the
Performance Scales than a one-dimensional model
(Table 3, 1.1.2). The two dimensions were interpreted as
(1) Visible Disability (mobility, spasticity, bladder),
describing the most visible and stigmatizing symptoms that
may make one home bound; and (2) Internal Disability
(hand function, fatigue, sensory, cognition), relating to an
internal, more subjective experience.
Step 2: Testing measurement invariance
across measurement occasions
The equality constraints imposed in this step led to a sig-
niﬁcant deterioration in ﬁt, suggesting the presence of
response shift (Table 3, Model 1.2.1). The modiﬁcation
indices and SEPCs suggested ﬁrst removing the equality
constraint on the intercept of ‘sensory’ for the stable
group at the ﬁrst measurement occasion (v
2diff(1) = 56.8,
P\0.001) and successively the intercept of ‘sensory’ for
1530 Qual Life Res (2011) 20:1527–1540
123Table 1 Descriptive statistics
for demographic variables of
Multiple Sclerosis patients for
Study 1 and Study 2
Variable Study 1 (n = 2,952) Study 2 (n = 1,767)
Sex
Male 423 (14.33%) 303 (17.15%)
Female 2,031 (68.80%) 1,464 (82.86%)
Age, mean (SD) 40.82 (9.35) 45.56 (9.31)
Time since diagnosis in years, mean (SD) NA 3.69 (2.12)
Newly diagnosed
Yes 1,054 (35.70%) NA
No/unknown 1,898 (64.30%)
Relapse
Yes (T1) NA 608 (34.41%)
Yes (T2) NA 565 (31.98%)
Yes (T3) NA 555 (31.41%)
Symptom change
T1 NA 3.64 (1.15)
T2 NA 3.61 (1.08)
T3 NA 3.64 (1.04)
Group membership
Stable 771 (26.12%) NA
Actively relapsing 1,552 (52.57%) NA
Progressing without relapsing 629 (21.31%) NA
Table 2 Means and standard deviations for Performance Scale items (Study 1) and SF-12 scales (Study 2)
Measurement
Occasions & Group Membership
Mobility Hand Function Fatigue Cognitive Bladder/Bowel Sensory Spasticity
Study 1—Performance Scales: higher scores indicate more disability
Time 1
Relapsing 1.52 (1.45) 1.22 (1.08) 2.58 (1.31) 1.62 (1.19) 1.18 (1.08) 1.89 (1.19) 1.51 (1.24)
Progressive 1.67 (1.47) 1.02 (0.98) 2.39 (1.26) 1.40 (1.17) 1.20 (1.04) 1.65 (1.17) 1.34 (1.22)
Stable 0.82 (1.17) 0.63 (0.86) 1.68 (1.22) 0.99 (1.01) 0.72 (0.90) 1.31 (1.03) 0.82 (1.05)
Time 2
Relapsing 1.65 (1.50) 1.25 (1.09) 2.68 (1.31) 1.74 (1.23) 1.29 (1.15) 1.83 (1.22) 1.60 (1.29)
Progressive 1.79 (1.56) 1.10 (1.05) 2.45 (1.31) 1.45 (1.12) 1.24 (1.05) 1.59 (1.13) 1.48 (1.27)
Stable 0.78 (1.21) 0.66 (0.89) 1.70 (1.25) 1.02 (0.97) 0.75 (0.91) 1.13 (0.98) 0.77 (0.96)
Time 3
Relapsing 1.75 (1.55) 1.31 (1.13) 2.70 (1.32) 1.77 (1.21) 1.37 (1.67) 1.84 (1.24) 1.65 (1.28)
Progressive 1.91 (1.67) 1.16 (1.07) 2.52 (1.28) 1.52 (1.16) 1.35 (1.10) 1.65 (1.16) 1.50 (1.29)
Stable 0.81 (1.24) 0.67 (0.88) 1.63 (1.25) 1.02 (1.25) 0.76 (0.91) 1.06 (0.96) 0.82 (0.99)
Measurement Occasions PF RF BP GH VT SF RE MH
Study 2—SF-12: higher scores indicate better health
Time 1 6.80 (2.34) 6.26 (2.47) 5.40 (2.52) 4.30 (1.93) 3.13 (2.04) 7.17 (2.38) 7.42 (2.28) 5.87 (1.73)
Time 2 6.86 (2.17) 6.34 (2.32) 5.41 (2.54) 4.37 (1.95) 3.16 (1.96) 7.03 (2.43) 6.98 (2.38) 5.81 (1.65)
Time 3 6.70 (2.44) 6.23 (2.50) 5.52 (2.68) 4.32 (1.93) 3.05 (2.07) 7.13 (2.43) 7.50 (2.31) 5.92 (1.72)
Sample sizes in Study 1 are relapsing = 1,552, progressive = 629, and stable = 771. Total sample size = 2,952. Total sample size in Study
2 = 1,767
PF Physical Functioning, RF Role Functioning, BP Bodily Pain, GH General Health, VT Vitality, SF Social Functioning, RE Role Emotional,
MH Mental Health
SF-12 means are sums of the items for each subscale and are not scaled to the standard 0–100 for computational convenience
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123the relapse group at the ﬁrst measurement occasion
(v
2diff(1) = 74.2, P\0.001). No further model modiﬁ-
cations were necessary. The ECVI difference tests were in
agreement with these modiﬁcations (Table 3).
As can be seen in Fig. 1a, at the second and third
measurement occasions, the intercepts of ‘sensory’ appear
to decrease for the stable (0.37–0.18) and relapsing groups
(0.37–0.18) relative to their Visible Disability (Fig. 1b).
This response shift can be interpreted as recalibration and
suggests that for these groups, when overall disability
increases over time, speciﬁc sensory disability did not
increase as much.
Step 3: Testing measurement invariance with respect
to exogenous variables
In the ﬁnal step, we used Model 1.2.2 and included addi-
tional exogenous variables (Table 3, Model 1.3.1). In all
groups, at all occasions, we found positive correlations
between age and both disability dimensions (see Table 4).
The other exogenous variables, ‘sex’, ‘newly diagnosed’,
‘time between measurement occasions 1 and 2’, and ‘time
between measurement occasions 2 and 3’ had correlations
less than 0.1 with disability. When inspecting the SEPCs,
we ﬁnd that none were above our cut point of 0.10.
Therefore, we concluded that there was no bias in the
Performance Scales items with respect to these variables.
See Fig. 1a and Table 4 for ﬁnal model estimates.
For each group, the estimates of the common factor
means of this ﬁnal model (Model 1.3.2) are plotted against
time in Fig. 1b and c. We see deterioration of progressive
and relapsing patients (increasing visible disability scores)
but no change in stable patients. There is little change
within groups for internal disability, stable patients have
the lowest internal disability means, and relapsing patients
have the highest internal disability means.
Study 1 conclusion
Only ‘‘sensory disability’’ showed response shift. Consid-
ering the impact of response shift and true change on
observed change in ‘sensory disability’, we see that an
observed change of -0.19 for stable patients is almost fully
attributable to response shift (-0.22), leaving only 0.03 of
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Fig. 1 a Performance Scale Measurement model at one measurement
occasion. Factor loadings and intercepts of Model 1.2.2. mobi
Mobility, spas Spasticity, blad Bladder/Bowel, hand Hand Function,
sens Sensory, fatig Fatigue, cogn Cognitive. b Visible Disability
Mean Change by Group and Between Models. c Internal Disability
Mean Change by Group and Between Groups. Note Scaling of
vertical axis is in standard deviations of the ﬁrst measurement
occasion common factor standard deviations
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123Table 4 Final model covariance and residual variance estimates
Visible–T1 Internal–T1 Visible–T2 Internal–T2 Visible–T3 Internal–T3
Variance/covariances
Visible–T1
Stable 1.10
Progressive 1.17
Relapsing 1.52
Internal–T1
Stable 0.38 0.52
Progressive 0.35 0.60
Relapsing 0.56 0.73
Visible–T2 1.26
Stable 0.99 0.36 1.98
Progressive 1.58 0.35 1.82
Relapsing 1.43 0.56
Internal–T2
Stable 0.35 0.40 0.42 0.47
Progressive 0.28 0.52 0.37 0.67
Relapsing 0.50 0.63 0.65 0.77
Visible–T3
Stable 0.97 0.34 1.20 0.39 1.22
Progressive 1.65 0.26 2.05 0.25 2.29
Relapsing 1.41 0.52 1.77 0.58 1.93
Internal–T3
Stable 0.32 0.39 0.38 0.42 0.40 0.48
Progressive 0.25 0.52 0.30 0.61 0.35 0.69
Relapsing 0.51 0.61 0.64 0.69 0.65 0.79
Sex
Stable -0.01 0.01 -0.02 0.01 -0.03 0.01
Progressive -0.09 \0.01 -0.08 -0.01 -0.09 -0.01
Relapsing -0.08 -0.02 -0.07 -0.01 -0.08 -0.01
Age
Stable 0.32 0.07 0.34 0.09 0.35 0.08
Progressive 0.43 0.04 0.50 0.02 0.51 0.01
Relapsing 0.37 0.12 0.43 0.14 0.43 0.13
Newly diagnosed -0.26 -0.12 -0.26 -0.12 -0.26 -0.12
Time between T1 and T2 0.10 0.01 0.10 0.01
Time between T2 and T3 0.10 0.01
Residual variances Mobility Spasticity Bladder/bowel Hand function Sensory Fatigue Cognitive
Stable
T1 0.27 0.59 0.53 0.40 0.61 0.74 0.48
T2 0.23 0.45 0.51 0.42 0.55 0.80 0.48
T3 0.30 0.43 0.51 0.38 0.51 0.88 0.51
Progressive
T1 0.41 0.82 0.77 0.60 0.82 0.79 0.75
T2 0.44 0.87 0.70 0.61 0.72 0.80 0.64
T3 0.40 0.81 0.80 0.60 0.76 0.80 0.67
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123true change. In the relapsing group, once we accounted for
a response shift of -0.18, we see that an observed change
of -0.06 underestimates a true change of 0.12. Still,
we note that these effect sizes should be considered
‘‘small’’.
Study 2 results
Participants were included if they had at least six of the 12
SF-12 items completed at three consecutive measurement
occasions that were 6 (±3) months apart. This yielded a
ﬁnal sample of 1,767 patients. See Table 1 for sample
characteristics and Table 2 for SF-12 observed scale
means.
Step 1: Establishing a measurement model
The SF-12 PF, RP, BP, and GH scales are associated with
PHYS, and VT, SF, RE, and MH are associated with
MENT [8]. When replicating this structure, this model had
only marginally satisfactory ﬁt (Table 3, Model 2.1.1).
Three sources of misﬁt were, at all measurement occasions,
as follows: 1) covariances between residuals of PF and RP
(v
2diff(9) = 549.6, P\0.001), 2) covariances between
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Fig. 2 a SF-12 Measurement model at one measurement occasion.
Factor loadings and intercepts of Model 2.2.2. PF Physical Func-
tioning, RF Role Functioning, BP Bodily Pain, GH General Health,
VT Vitality, SF Social Functioning, RE Role Emotional, MH Mental
Health. b PHYS HRQoL Mean Change Between Models. c MENT
HRQoL Mean Change Between Models. Note Scaling of vertical axis
is in standard deviations of the ﬁrst measurement occasion common
factor standard deviations
Table 4 continued
Residual variances Mobility Spasticity Bladder/bowel Hand function Sensory Fatigue Cognitive
Stable
T1 0.57 0.83 0.76 0.58 0.76 0.77 0.72
T2 0.40 0.83 0.79 0.58 0.79 0.74 0.73
T3 0.43 0.76 0.86 0.61 0.78 0.73 0.67
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123residuals of MH and RE (v
2diff(9) = 452.5, P\0.001),
and 3) cross-loadings of VT on PHYS (v
2diff(3) = 156.0.2,
P\0.001). These modiﬁcations produced a measurement
model with satisfactory ﬁt (Table 3, Model 2.1.2).
Step 2: Testing measurement invariance
across measurement occasions
The equality constraints imposed in this step led to sig-
niﬁcantly deteriorated ﬁt, suggesting the presence of
response shift (Table 3, Model 2.2.1). The global test
associated with the scale RE resulted in the largest OPCs
and a signiﬁcant chi-square difference test. Therefore, the
parameters associated with RE were free to be estimated
(Fig. 2a). As can be seen in Fig. 2a, the intercept of RE at
the second measurement occasion was lower (7.1) than at
the ﬁrst and third measurement occasions (7.4 and 7.5).
This suggests that there is uniform recalibration for the RE
scale: Patients seemed less inclined to report high RE at the
second measurement occasion as compared to the ﬁrst and
third measurement occasions, given similar MENT
HRQoL. No further response shifts were found.
Step 3: Testing measurement invariance with respect
to exogenous variables
Adding additional exogenous variables to Model 2.2.2
resulted in a satisfactorily ﬁtting model (Table 3, Model
2.3.1). We found large negative correlations of age and
relapse with PHYS and MENT and positive correlations of
symptom change with PHYS and MENT. The correlations
between sex and time since diagnosis and PHYS and
MENT are considered very small (\0.01) (Table 5). With
Model 2.3.1 as the comparison model, we proceeded to test
for bias with respect to the exogenous variables using the
global tests and OPCs. Signiﬁcant direct effects of age on
MH (Model 2.3.2) were found. We also found signiﬁcant
direct effects of age on VT (Model 2.3.3). In the next
iteration, no further signiﬁcant effects were found.
We tested whether the measurement bias in MH and VT
with respect to age was consistent across measurement
occasions. As the inclusion of equality constraints across
measurement occasions did not worsen model ﬁt (v
2diff
(4) = 7.80, P = 0.099), we concluded that the bias is con-
sistent and did not indicate response shift. Given the negative
correlations between age and PHYS and MENT (Table 5),
Table 5 Final model variance/covariances and residual variance estimates
PHYS
HRQoL –T1
MENT
HRQoL –T1
PHYS
HRQoL –T2
MENT
HRQoL –T2
PHYS
HRQoL –T3
MENT
HRQoL –T3
Variance/Covariances
PHYS HRQoL –T1 1
MENT HRQoL –T1 0.87 1
PHYS HRQoL –T2 0.87 0.78 0.94
MENT HRQoL –T2 0.81 0.81 0.84 0.95
PHYS HRQoL –T3 0.91 0.80 0.90 0.83 1.05
MENT HRQoL –T3 0.77 0.78 0.77 0.81 0.91 0.98
Sex -0.03 0.002 -0.01 -0.01 -0.02 -0.005
Age -0.25 -0.12 -0.21 -0.13 -0.26 -0.13
Time since diagnosis -0.04 0.02 0.01 -0.05 -0.02 -0.03
Symptom change–T1 0.63 0.52 0.52 0.48 0.52 0.39
Symptom change–T2 0.52 0.42 0.61 0.53 0.57 0.41
Symptom change–T3 0.41 0.36 0.42 0.39 0.60 0.49
Relapse–T1 -0.15 -0.15 -0.13 -0.12 -0.13 -0.12
Relapse–T2 -0.13 -0.13 -0.15 -0.14 -0.14 -0.12
Relapse–T3 -0.12 -0.11 -0.13 -0.11 -0.17 -0.14
PF RP BP GH VT SF RE MH
Residual variances
T1 2.27 1.66 3.24 1.68 1.97 1.31 2.65 1.76
T2 1.99 1.62 3.28 1.65 1.82 1.56 2.61 1.67
T3 2.51 1.60 3.91 1.64 2.02 1.62 2.59 1.79
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123the bias on MH (0.20) and VT (0.19) with respect to age
suggests that older patients reported better MH and VT
than was expected. The estimates of the common factor
means of this model (Model 2.3.3) did not show any
change (Fig. 2b and c).
Study 2 conclusion
When we consider the impact of response shift and true
change on observed change in EF, we see that the observed
change of 0.23 is almost fully attributable to response shift
(0.17), leaving only 0.06 of true change. However, only on
thesecondmeasurementoccasion,wefoundanindicationof
response shift in EF, which hinders substantive interpreta-
tion. So we concluded that this may be a chance ﬁnding.
Discussion
We have illustrated two different ways in which SEM can
be used to investigate response shift. With the present data,
we found uniform recalibration response shift in the sensory
disability item of the Performance Scales (Study 1),
indicating that stable and relapsing patients initially over-
estimate their sensory disability. Apparently, in comparison
with their general performance disability, they initially
worry more about their sensory disability but then become
accustomed to their situation, whereas progressive patients
continuetodeteriorateintheirperformancedisabilityand,as
aresult,donotbecomeaccustomedtosensorydisability.Ina
study investigating progressive MS patients, it was shown
that the presence of sensory disability led to an increased
length of time to reach a severe level of disability [20]. In
another study comparing progressive and relapsing patients,
itwasfoundthatrelapsingpatientshadhigherinitialsensory
disability than progressive patients [21]. It may be possible
that the gradual progression of disease seen in progressive
patientsleadstoaslightworseningofsensorydisabilityover
time, which is difﬁcult to become accustomed to.
We did not ﬁnd clearly interpretable response shift in
the SF-12 (Study 2), nor did we ﬁnd any change in HRQoL.
However, two measurement biases that are not response
shift, as they are constant across measurement occasions,
were found: age on MH and age on VT. The correlations
between age and PHYS and MENT HRQoL are negative;
however, the direct effects of age on MH and VT are
positive. This suggests that increased age affects MH and
VT in a different way than would be expected due to the
correlations between the age and the common factors.
A possible explanation for the limited response shift
ﬁndings is that the NARCOMS registry patients are not
subjected to a planned intervention, so there is no clear
catalyst of health state changes, other than self-reported
relapse and symptoms. Therefore, the sizes of the response
shifts found are small, and accounting for these response
shifts does not cause large effects on the mean change in
performance disability or HRQoL. Though importantly, the
response shifts do change the interpretation of the observed
changes. In Study 1 for the stable patients and in Study 2
for all patients, the response shift accounts for essentially
all observed change, leaving essentially no true change.
With the relapsing patients in Study 1, the observed change
is underestimated, and after taking response shift into
consideration, true change appears small and negative.
These two studies highlight how SEM can be used to
detect measurement bias under different circumstances.
The steps used are hierarchical; however, there is the
ﬂexibility (1) to account for health state by splitting the
sample into subsamples or by including exogenous vari-
ables, (2) to use time-varying or time-constant exogenous
variables, (3) to use different search strategies for detecting
response shift, (4) inclusion of ﬁxed or random measure-
ment occasions and, not discussed in this paper, (5) to
investigate different longitudinal structures like autore-
gressive and latent growth curve structures [22]. Some of
these decisions are made based on the design of the study
or sample size available, and for each decision made there
are trade-offs. A persistent problem is that the decision of
when to stop investigating measurement bias is relatively
subjective. Because of the large number of tests to con-
sider, despite our strict criteria for what we consider
response shift, we still need to guard against chance ﬁnd-
ings [18]. Still, SEM offers a useful statistical approach for
response shift detection as it can be tailored to the speciﬁcs
of the study design.
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Appendix 1
Study 1
Step 1: Establishing a measurement model
The Performance Scales were originally reported to be a
unidimensional construct [7]. If the conﬁrmatory factor
analysis (CFA) used to assess the longitudinal multigroup
uni-dimensional model does not ﬁt, then exploratory factor
Qual Life Res (2011) 20:1527–1540 1537
123analysis is used to determine an alternative model, and the
ﬁt of this model is assessed using CFA.
Maximum likelihood estimation is used for parameter
estimation. We assess the overall ﬁt of our models with the
chi-square test of exact ﬁt, the root mean square error of
approximation (RMSEA) [12], the expected cross-valida-
tion index (ECVI) [12], the comparative ﬁt index (CFI)
[10], and the Tucker Lewis index (TLI) [11]. Emphasis,
however, is placed on the RMSEA and ECVI ﬁt statistics
as conﬁdence intervals can be calculated for these ﬁt sta-
tistics. A non-signiﬁcant chi-square value indicates good
ﬁt. As it is sensitive to small deviations between model and
data, especially when the sample size is large, we also
consider approximate ﬁt indices that relax the stringent
requirement on chi-square that the model has exact ﬁt to
the population. RMSEA\.08 indicates satisfactory ﬁt;
RMSEA\.05 indicates close ﬁt. ECVI cannot be used as
a stand-alone index but can be used to compare alternative
models; a smaller ECVI value suggests better model ﬁt
[12]. Finally, both the CFI and the TLI assess the
improvement in ﬁt from a null model with no relationships
assumed between variables. Values [.95 for the CFI and
[.90 for the TLI indicate reasonable ﬁt of the model to
data.
If a new model is speciﬁed due to misﬁt as indicated by
modiﬁcation indices, standardized residuals or standard-
ized expected parameter changes (SEPC), then the change
in overall model ﬁt is assessed with the chi-square differ-
ence test and the ECVI difference test [13]. The chi-square
difference test is used to assess whether the alternative
model ﬁt is signiﬁcantly better than the ﬁt of the null
model. A signiﬁcant result indicates that the alternative
model has better ﬁt than the null model. The ECVI dif-
ference is the difference between the ECVI values of the
null and alternative models. If the conﬁdence interval of
this test does not include zero, then the change is signiﬁ-
cant. The ECVI test is based on the chi-square test but it
penalizes models containing more free parameters [13].
Step 2: Testing invariance across measurement occasions
In this step, we take the ﬁnal model of Step 1 and simul-
taneously constrain all factor loadings and intercepts to be
equal across measurement occasions and groups. Across-
occasion invariance (lack of measurement bias) of the
factor loadings and intercepts is assessed by comparing this
model with the ﬁnal model of Step 1 using the chi-square
difference test. A signiﬁcant test provides strong evidence
that response shift is present as it is possible that the
equality constraints imposed are not tenable. However, if
the test is not signiﬁcant, it may still be possible that one of
the equality constraints is not tenable. Therefore, we still
search for bias, as a single, yet substantially important
response shift may not cause signiﬁcant deterioration in the
overall model ﬁt.
To detect measurement bias, we examine modiﬁcation
indices and SEPCs [13]. One prerequisite for meaningful
model respeciﬁcation is that large modiﬁcation indices are
substantively interpretable; however, this alone does not
ensure a substantial change in the parameter estimate,
especially in large samples. Therefore, we also consider the
associated SEPC. If both are large, then there is a signiﬁ-
cant improvement in the overall model and substantial
change in the parameter estimate. As there are a large
number of modiﬁcation indices to consider, we stop
investigating modiﬁcation indices when none are greater
than 12.83 [14]. This critical value has been adjusted for
the number of tests in consideration so as to maintain a
family-wise type 1 error rate of 5%. For the SEPCs, we
consider[0.10 signiﬁcant [15]. The impact of any response
shift found is assessed by using Oort’s [2] partitioning
formula to evaluate the contribution of response shift and
true change in terms of Cohen’s effect size d [16].
Step 3: Testing invariance with respect
to exogenous variables
Using the ﬁnal model in Step 2, we now include ‘age’,
‘sex’, ‘newly diagnosed’, ‘time between measurement
occasions 1 and 2’, and ‘time between measurement
occasions 2 and 3’ as additional exogenous variables.
These ﬁve exogenous variables correlate with each other
and with the common factors, but their relationship with
the observed items should be fully explained by these
correlations. If large modiﬁcation indices and SEPCs are
present between the exogenous variables and the observed
items, this is an indication of bias and requires the esti-
mation of direct effects. If the estimates of the direct effects
change over time (i.e., cannot be constrained to be equal
across measurement occasions), we interpret this as
response shift. However, if the direct effects do not change
over time, we consider this measurement bias. Large
modiﬁcation indices and SEPCs will be evaluated using the
same criteria as outlined in Step 2.
Appendix 2
Study 2
Step 1: Establishing a measurement model
The ﬁrst goal is to ﬁnd a satisfactory measurement model
for the SF-12. We begin with the measurement model
comprising two common factors: PHYS and MENT
HRQoL. If this model does not ﬁt, we use modiﬁcation
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123indices and standardized residuals [13, 18] to identify
misspeciﬁcation and develop an alternative model. As we
are evaluating the measurement model longitudinally, we
require the same observed variables to be associated with
the same common factors across measurement occasions. If
the model is modiﬁed, the changes are assessed using the
chi-square difference test and ECVI difference test as
explained in Study 1. Overall model ﬁt is assessed using
the same statistics as used in Study 1.
Step 2: Testing invariance across measurement occasions
Using the ﬁnal measurement model from Step 1, all factor
loadings and intercepts of the ﬁnal model of Step 1 are
simultaneously constrained to be equal across measurement
occasions, like in Study 1. The assessment of overall model
ﬁt and change in model ﬁt compared to the ﬁnal model of
Step 1 are again done in the same way as in Study 1.
To detect response shift, we use a different search
strategy from Study 1 where we test individual constraints.
Here, we follow the procedure outlined in King-Kallimanis
et al. [19], where all observed scales are tested with a
smaller number of global tests that free multiple constraints
simultaneously. In this study, we use eight global tests, one
for each observed scale. That is, for each of the eight
scales, the equality constraints on both the factor loadings
and the intercepts at all three measurement occasions are
removed. The ﬁt of each of these eight new models is
compared to the fully constrained model using the chi-
square difference test. The impact of freeing the parameters
on the estimated parameter values is assessed by calculat-
ing the observed parameter changes (OPC). The OPCs are
scaled for ease of comparison, and they are the actual
difference between the standardized factor loadings and
intercepts of the null model, and the standardized factor
loadings and intercepts of the altered model. Correspond-
ing to Cohen’s small effect sizes, we consider an OPC
indicating a difference of 0.1 between factor loadings or
0.2 between intercepts to be large [16]. We consider both
values because small deviations in the observed and
expected covariance matrix may lead to signiﬁcant model
improvement, but not substantial parameter change.
After running the eight tests, the model speciﬁcs are
checked. In particular, scales with OPCs that meet our
criteria that are in conjunction with a signiﬁcant chi-square
difference test are considered as exhibiting response shift.
The factor loadings and intercepts of this scale remain
unconstrained, and the remaining scales are retested with
an adjusted signiﬁcance level. We continue iteratively
retesting the remaining scales, until no large OPC with
signiﬁcant chi-square difference test is found.
Although there are fewer tests to consider when using
the global tests, when the number of iterations increases, so
does the number of tests. Therefore, when considering the
signiﬁcance of the chi-square difference test, we use a
Bonferroni-adjusted level of signiﬁcance, with the family-
wise level of signiﬁcance at 5% divided by the number of
tests under consideration for this particular step of the
analysis [14].
Step 3: Testing invariance with respect to exogenous
variables
We extend the ﬁnal model of Step 2 to include ‘age’, ‘sex’,
‘time since diagnosis’, ‘relapse in the past 6 months’, and
‘symptom change in the last 6 months’ as exogenous
variables. We hypothesize that these variables have the
potential to induce bias on the observed scales. These
additional variables are free to correlate with each other
and with the common factors; however, all direct effects
between the observed scales are ﬁxed to zero. To test for
response shift, we ﬁt new models where the direct effects
of the exogenous variables are free to be estimated. For
example, for ‘sex’ we ﬁt eight new models, with the effect
of sex on an observed scale for three measurement occa-
sions. This results in three additional parameters to be
estimated. The impact of these direct effects is assessed
with OPCs and the chi-square difference test. If the largest
effects meet our criteria like in Step 2, we leave these
parameters free to be estimated and start the process over
again and stop when no freed direct effects meet our cri-
teria. Once any biases have been accounted for, this ﬁnal
model can be used to assess true change in the attribute of
interest using the same partitioning formula we use in
Study 1.
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